Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

Cai Hongfu; Zhang Longfeng; Li Na; Chen Shen; Zheng Bin; Yang Jing; Weng Lizhu; Liu Mao-Bai

首页> 外文期刊>Clinical therapeutics >Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

【24h】

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

机译：Esimertinib的成本有效性作为中国EGFR突变阳性非小细胞肺癌的一线治疗和顺序治疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose: This study aimed to evaluate the cost-effectiveness of osimertinib with gefitinib or erlotinib as first-line and sequential therapy for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in China.

机译：目的：本研究旨在评估与吉替尼或奥尔洛替尼作为表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）的一线和顺序治疗的成本效益。

著录项

来源
《Clinical therapeutics》 |2019年第2期|共11页
作者
Cai Hongfu; Zhang Longfeng; Li Na; Chen Shen; Zheng Bin; Yang Jing; Weng Lizhu; Liu Mao-Bai;
展开▼
作者单位

Fujian Med Univ Union Hosp Dept Pharm 29 Xinquan Rd Fuzhou 350001 Fujian Peoples R China;

Fujian Prov Canc Hosp Dept Med Oncol Fuzhou Fujian Peoples R China;

Fujian Med Univ Union Hosp Dept Pharm 29 Xinquan Rd Fuzhou 350001 Fujian Peoples R China;

Ctr ADR Monitoring Fuzhou Fuzhou Fujian Peoples R China;

Fujian Med Univ Union Hosp Dept Pharm 29 Xinquan Rd Fuzhou 350001 Fujian Peoples R China;

Fujian Med Univ Union Hosp Dept Pharm 29 Xinquan Rd Fuzhou 350001 Fujian Peoples R China;

Fujian Med Univ Sch Pharm Fuzhou Fujian Peoples R China;

Fujian Med Univ Union Hosp Dept Pharm 29 Xinquan Rd Fuzhou 350001 Fujian Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
cost-effectiveness; first-line treatment; NSCLC; osimertinib;

机译：成本效益;一线治疗;NSCLC;Osimertinib;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China [J] . Cai Hongfu, Zhang Longfeng, Li Na, Clinical therapeutics . 2019,第2期

机译：Esimertinib的成本有效性作为中国EGFR突变阳性非小细胞肺癌的一线治疗和顺序治疗
2. Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy [J] . Wu Bin Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第5期

机译：响应：在初级EGFR酪氨酸激酶抑制剂治疗后进展后，对EGFR突变阳性非小细胞肺癌进行EGFR突变阳性非小细胞肺癌的成本效益评论
3. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy [J] . Wu Bin, Gu Xiaohua, Zhang Qiang Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第2期

机译：在初始EGFR TKI治疗后，EAGFRINIB对EGFR突变阳性非小细胞肺癌的成本效益
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Application of Quantitative Metrics for EGFR-Targeted Non-Small Cell Lung Cancer Therapy Using [11C]Erlotinib PET. [D] . Petrulli, Joseph Ryan. 2017

机译：定量指标在EGFR靶向非小细胞肺癌治疗中的应用[11C]厄洛替尼PET。
6. A Real-World Observational Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：真实世界观测性前瞻性研究以评估表皮生长因子受体（EGFR）突变的分子流行病学在一线治疗中或二进代EGFR酪氨酸激酶抑制剂在EGFR突变局部局部先进或转移性非小细胞肺癌：悠久的研究
7. CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER [O] . M.S. Holleman, M.J. Al, C.A. Uyl-de Groot 2018

机译：CE4 - EGFR突变阳性非小细胞肺癌患者一线Osimertinib的成本效益分析

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅